Clinical Trial Update: QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of the Phase 1/2 study QUILT-3.040 evaluating ETBX-011 vaccine in combination with ALT-803 for CEA-expressing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Thyroid Cancer

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)
• ETBX-011 (Ad5 (E1-, E2b-) CEA(6D) vaccine)

Snippet

Sponsor: NantCell, Inc. | Conditions: Thyroid Cancer, Colon Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-06